聚乙二醇脂质体多柔比星治疗复发性卵巢癌的研究进展  

Research Progress of Polyethylene Glycol Liposome Doxorubicin in the Treatment of Recurrent Ovarian Cancer

作　　者：张亚丽 孔宪超(审校)[1] ZHANG Ya-li;KONG Xian-chao(Department of Obstetrics and Gynecology,The Second Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第二医院妇产科,150001

出　　处：《国际妇产科学杂志》2022年第2期212-216,共5页Journal of International Obstetrics and Gynecology

摘　　要：卵巢癌发病隐匿,复发率和致死率高,严重威胁妇女生命和健康。近年来,药物纳米技术的发展为肿瘤治疗提供了新的机遇。聚乙二醇脂质体多柔比星(polyethylene glycol liposome doxorubicin,PLD)是将多柔比星包埋于聚乙二醇脂质体中所制成的小分子纳米颗粒,因较强的靶向性、对骨髓和心脏的低毒性、药物在体内的稳定性,现作为新型多柔比星纳米制剂被广泛应用。已证实不论是PLD单药或联合使用,均可有效改善复发性卵巢癌患者的生存时间。综述PLD在复发性卵巢癌中单药或联合曲贝替定或联合铂类药物及维持治疗的研究进展,旨在寻找更为安全有效且个体化的临床治疗方案。Ovarian cancer is insidious and has a high recurrence rate and mortality rate,which seriously threatens women′s life and health.In recent years,the development of pharmaceutical nanotechnology has provided new opportunities for tumor therapy.Polyethylene glycol liposome doxorubicin(PLD)is a small molecular nano particle made by embedding doxorubicin in polyethylene glycol liposomes.It is widely used as a new doxorubicin nano preparation because of its strong targeting,low toxicity to bone marrow and heart and stability of drugs in vivo.It has been proved that PLD alone or in combination can effectively improve the survival time of patients with recurrent ovarian cancer.This paper reviews the research progress of PLD in the treatment of recurrent ovarian cancer with single drug,or combined with trabecotidine,or combined with platinum drugs and maintenance therapy,in order to find a more safe,effective and individualized clinical treatment.

关 键 词：多柔比星 聚乙烯二醇类 脂质体 卵巢肿瘤 肿瘤复发 局部 铂 

分 类 号：R737.31[医药卫生—肿瘤]